Soligenix Announces Presentation of OrbeShield™ Data at Annual Radiation Research Society Meeting

Princeton, NJ – September 28, 2012 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that results of a study in a canine model of OrbeShield™ (oral beclomethasone 17,21-dipropionate) will be presented at a poster session entitled, “Post-exposure oral 17,21-beclomethasone dipropionate (BDP) improves survival in a canine gastrointestinal acute radiation syndrome (GI ARS) model.” The presentation will be made during the 58th Annual Meeting of the Radiation Research Society to be held in San Juan, Puerto Rico on September 30 through October 3, 2012.

Continue reading

Advertisements

Tags: , ,

Categories: Life Sciences Industry Network

Author:NJ Tech Council

The New Jersey Tech Council helps companies grow and supports the tech, innovation and entrepreneurial ecosystems in the state and region.

NJTC TechWire

Daily updates about the region's most tech savvy companies

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: